Tara Williamson

Title: Innovations in Cancer Treatment: The Work of Tara Williamson

Introduction

Tara Williamson is an accomplished inventor based in Baltimore, MD (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of pharmaceuticals. Her work focuses on repurposing existing drugs to enhance their efficacy in treating various forms of cancer.

Latest Patents

Tara Williamson holds a patent for a novel application of Mebendazole, titled "Mebendazole polymorph for treatment and prevention of tumors." Mebendazole is an antiparasitic drug that has been safely used for over 40 years. Recently, it has been repurposed for glioblastoma therapy. There are three polymorphs of Mebendazole, but the therapeutic relevance of these different forms was previously unknown. Williamson's research indicates that Mebendazole polymorph C is a superior oral form that effectively reaches the brain and brain tumors. The efficacy of this treatment is further enhanced when combined with a P-glycoprotein inhibitor. Additionally, Mebendazole may serve as a therapeutic agent for other cancers and as a chemo-preventative agent.

Career Highlights

Tara Williamson is affiliated with The Johns Hopkins University, where she conducts her research. Her work has garnered attention for its potential to change the landscape of cancer treatment. With a focus on innovative drug repurposing, she aims to improve patient outcomes and expand treatment options for various cancers.

Collaborations

Tara collaborates with esteemed colleagues, including Gregory J Riggins and Renyuan Bai. Their combined expertise contributes to the advancement of cancer research and the development of effective treatment strategies.

Conclusion

Tara Williamson's innovative work in the field of cancer treatment exemplifies the potential of repurposing existing drugs to enhance therapeutic efficacy. Her contributions are paving the way for new treatment options that could significantly impact patient care.